Why Nothing Ever Hit Like OG Jack3d

Main Ideas

1. Why the Original Jack3d Felt Unusually Powerful

The narrator says the original Jack3d combined DMAA, caffeine, and beta-alanine in a small serving. He explains its intense “hit” as a combination of effects:

• DMAA appears to increase norepinephrine activity, stimulating the body’s fight-or-flight response and raising heart rate and blood pressure.
• Caffeine blocks adenosine, reducing a natural “braking” effect rather than directly creating the same stimulant drive.
• Beta-alanine can cause skin tingling, adding to the sensation of intensity.
• The product’s proprietary blend did not disclose the amount of each ingredient. Reported laboratory measurements of DMAA varied widely, leaving the actual dose uncertain.

The narrator characterizes the result as intense arousal and a feeling of invulnerability—not simply a dopamine-driven “high.” He also emphasizes that this mechanism could pose cardiovascular risks, especially during strenuous exercise, in heat, with dehydration, or after sleep deprivation.

2. DMAA’s Origins and Its Path Into Supplements

The story begins with a compound patented by Eli Lilly chemists in the 1940s and later sold as a nasal decongestant. It constricted blood vessels to reduce nasal swelling. Historical references described possible nervousness, agitation, and tremors.

After the product was withdrawn, the narrator says DMAA reappeared decades later as a supplement ingredient called Geranamine. Its claimed connection to geranium oil rested largely on a 1996 Chinese-language paper reporting a small amount of DMAA in geranium oil. Later tests reportedly found no DMAA in authentic geranium plants or oils, and Health Canada and a supplement-industry trade group questioned or rejected the plant-origin claim.

The video says DMAA was instead synthetic. It cites correspondence and an indictment alleging that suppliers discussed forged certificates describing the synthetic substance as a plant extract. These allegations later formed part of a case in which company figures pleaded guilty to crimes.

3. The Regulatory Gap That Enabled the Products

The narrator links DMAA’s rise to the 2004 FDA ban on ephedra, which left a market for potent stimulants. He describes the Dietary Supplement Health and Education Act of 1994 (DSHEA) as allowing ingredients onto the market through a relatively limited notification process, rather than requiring the FDA to approve their safety before sale.

According to the video:

• A company needed a basis for treating an ingredient as having a history of use in food, or had to notify the FDA before marketing a new dietary ingredient.
• The FDA was not told about DMAA’s use as a supplement when it first appeared, despite testing and media attention.
• The FDA took years to issue warning letters. The narrator says its legal action focused on the missing notification and the ingredient’s status—not on proving that DMAA caused particular deaths.

4. Jack3d and OxyElite Pro

USPlabs launched Jack3d around 2008, combining DMAA with other familiar pre-workout ingredients. The company also sold OxyElite Pro, a stimulant-based weight-loss supplement launched in 2009. The video says DMAA products generated substantial sales and that USPlabs reported very high numbers of servings consumed.

The narrator describes OxyElite Pro as tapping into demand for non-prescription weight-loss stimulants. At the time, many prescription weight-loss drugs were stimulants, while newer medications had not yet become available.

5. Health Concerns, Reported Deaths, and Limits of the Evidence

The video describes positive drug tests and health concerns associated with DMAA:

• WADA added DMAA to its banned-substance list in 2010, and the narrator says it became a frequent cause of positive tests.
• The U.S. military reportedly removed DMAA products from its stores in 2011 after concerns involving soldiers.
• The video recounts the deaths of two U.S. service members and a London Marathon runner who had taken DMAA-containing products. In the marathon case, a coroner concluded that the supplement, in combination with excessive exercise, was likely to have contributed to acute heart failure.

However, the narrator stresses that direct causation was not conclusively established in the deaths. He notes that military experts considered DMAA’s role unlikely or unproven in some cases, and that a family’s lawsuit was dismissed after its causation experts were rejected. His view is that DMAA’s effects could raise risk under extreme exertion, but the available evidence does not prove that it directly caused those deaths.

6. The Reformulation and Hawaii Liver-Injury Outbreak

While the FDA was pressuring companies to remove DMAA, USPlabs introduced a new OxyElite Pro formula containing aegeline, described as a synthetic version of a compound associated with the bael tree. The narrator says this ingredient had no established human safety record in supplements and that the company did not submit the required notification.

In 2013, Hawaii health officials reported acute hepatitis and liver failure among people who had used OxyElite Pro. The video cites a nationwide count of 97 cases, including 47 hospitalizations, three liver transplants, and one death. The deceased woman, Sonette Marris, was a 48-year-old mother of seven.

The narrator identifies aegeline as the leading suspect but repeatedly qualifies the conclusion:

• Aegeline has not been definitively proven to be toxic in these cases.
• OxyElite Pro also contained green tea extract, which can itself be associated with liver injury.
• Later laboratory work reportedly found that aegeline can be converted in the liver into a reactive metabolite.
• Some patients had used an older formula without problems but became ill after switching to the new one.

The video also alleges that USPlabs tried to sell remaining stock quickly, including efforts to move product out of the country and sell it without creating a paper trail. These details are presented as allegations in prosecutorial materials.

7. Enforcement and the Wider Supplement Market

The FDA issued warning letters about DMAA products in 2012. USPlabs later said it was removing DMAA for “business reasons.” In 2013, the FDA seized and destroyed millions of dollars’ worth of product.

The narrator says the company subsequently faced federal charges related to fraud, mislabeling, obstruction, and money laundering. In 2019, USPlabs and several individuals pleaded guilty. The company agreed to shut down, and executives received prison sentences and financial penalties.

He argues that banning one stimulant did not solve the underlying problem. The market moved to other stimulant-like compounds marketed as plant-derived ingredients, including BMPEA, DMBA, methylsynephrine, and DMHA. The video cites testing and enforcement figures suggesting that banned stimulants sometimes remained in products even after public warnings.

The narrator’s broader conclusion is that the regulatory framework encourages substitution: companies can replace one questioned ingredient with another, while the FDA often responds after products are already on shelves. He criticizes the system but also voices skepticism about giving the FDA more authority.

Practical Takeaway

The narrator advises consumers to be cautious with pre-workouts that:

• Use a proprietary blend that hides ingredient amounts.
• List unfamiliar stimulants under vague or plant-based names.
• Make strong stimulant claims without clear safety information.

His central warning is to investigate unfamiliar active ingredients rather than assuming that a plant-sounding label means the substance is naturally sourced or well tested.

Speakers and Sources Featured

• Dr. Alex Tatem — host and primary narrator.
• Ronik/Ronnie — off-camera production colleague addressed by the host; no extended substantive commentary appears in the subtitles.
• Superpower — video sponsor, discussed in a promotional segment about blood testing.

Sources Cited or Described by the Narrator

• FDA letters, statements, seizure actions, and recall authority.
• U.S. Department of Justice announcements and federal indictment materials.
• Court records and guilty pleas.
• The 1940s Eli Lilly patent and historical pharmaceutical references, including the U.S. Dispensatory.
• The Dietary Supplement Health and Education Act of 1994.
• The Washington Post reporting and laboratory testing.
• Scientific studies on DMAA’s effects, geranium testing, and aegeline metabolism.
• Health Canada and a supplement-industry trade association.
• WADA and IOC announcements.
• U.S. Army and Pentagon safety reviews.
• Hawaii Department of Health, CDC, and the Liver Injury Research Network.
• The London Marathon runner’s coroner’s report.